Evolus, Inc. (EOLS) reported that it entered into a material licensing, supply and distribution agreement with IBSA Institut Biochimique SA on July 7, 2026, expanding Evolus’s aesthetics portfolio with U.S. rights to Profhilo, an injectable hyaluronic acid product used for skin-quality applications. Under the agreement, IBSA granted Evolus an exclusive right and license to develop, commercialize and distribute Profhilo in the United States for use in the aesthetics and dermatological fields. The deal also gives Evolus rights to negotiate for certain additional products in the Profhilo brand family and related line extensions in the same U.S. field. Evolus will be responsible, at its own expense, for U.S. development, clinical work and regulatory activities needed to support Food and Drug Administration approval of the initial Profhilo product. If approved, Evolus will hold the resulting U.S. regulatory approval and related regulatory materials. After FDA approval, Evolus will buy the product from IBSA under a transfer-pricing model, with terms subject to periodic adjustment under the agreement. Notably, the agreement does not require Evolus to make any upfront payment or milestone payments to IBSA. However, it includes minimum purchase requirements beginning in the fourth year after commercial launch of the initial product. If Evolus fails to meet those minimum purchase obligations, its exclusive rights may be converted to non-exclusive rights or the agreement may be terminated, subject to certain exceptions. The initial term of the agreement is 15 years from the first FDA approval of the initial product. The arrangement may renew for successive five-year terms, subject to the agreement’s conditions. The filing was made under Item 1.01, Entry into a Material Definitive Agreement. Evolus also disclosed under Item 7.01 that it issued a press release on July 8, 2026, announcing the agreement, and listed that press release as Exhibit 99.1 under Item 9.01. The company said the full agreement will be filed as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2026. The report does not describe any stock issuance, insider transaction, share purchase or sale, transaction code, share count, exercise price or ownership change. Its significance is strategic rather than securities-transaction-related: Evolus is seeking to add a new injectable hyaluronic acid skin-quality product to its U.S. aesthetics platform without paying upfront or milestone consideration, while taking on the cost and responsibility of U.S. regulatory development.